Currentpriority healthPolicy N/A

Arthrocentesis, Aspiration, Injection

Defines coding, billing, documentation, modifier use, drug reporting, and utilization limits for arthrocentesis, aspiration, injections, and trigger point injections for Priority Health providers.

Policy Summary

Payerpriority health

PolicyArthrocentesis, Aspiration, Injection

Policy CodePolicy N/A

Change TypeAdded modifier sectionrelated denial language

Effective DateN/A

Next Review DateN/A

Key ActionEnsure documentation supports anatomical location, muscles injected, drug names/NDCs and units; submit appropriate modifiers (e.g., EJ for hyaluronan series).

SourceLink

POLICY UPDATE CHANGES

Added 'Disclaimer' section.

Updated the policy name to 'Arthrocentesis, Aspiration, Injection'.

Added Modifier Section.

Added Related Denial Language.

4trigger point injection sessions allowed per rolling year

20552,20553CPT codes for trigger point injections

20610,20611CPT codes for major joint arthrocentesis/aspiration/injection

Multiple J7XXXHyaluronan HCPCS & dosing guidance

Coverage Criteria and Billing Rules

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Procedure and Drug Coding

Primary procedure CPT codesCPTCovered

20552	Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)
20553	Injection(s); single or multiple trigger point(s), 3 or more muscles
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa; without ultrasound guidance
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting

Hyaluronan/viscosupplement HCPCS codes and dosingHCPCSCovered

J7321	Hyalgan / Supartz / Visco-3 dosing per knee: series 3 to 5 weekly injections (Hyalgan 20 mg once weekly; Supartz 25 mg once weekly; Visco-3 25 mg once weekly); units = 1
J7323	Euflexxa dosing per knee: 3 weekly injections; 20 mg once weekly; units = 1
J7324	Orthovisc dosing per knee: 3 to 4 weekly injections; 30 mg once weekly; units = 1
J7326	Gel-One single injection dosing per knee: 30 mg x 1 dose; units = 1
J7327	Monovisc single injection dosing per knee: 88 mg x 1 dose; units = 1
J7328	Gelsyn-3 dosing per knee: 3 weekly injections; 16.8 mg once weekly; units = 168 (per 0.1 mg unit)
J7329	TriVisc dosing per knee: 3 weekly injections; 25 mg once weekly; units = 25 (per 1 mg unit)

Hyaluronan dosing and frequency alignment

RequirementDosage and frequency must align with FDA‑approved dosing per the listed HCPCS codes (product-specific series range from single injection up to 3–5 weekly injections).

EJ modifierThe EJ modifier must be used when reporting subsequent injections within a hyaluronan series; failure to report will result in denial.

Product examples and seriesExamples: J7321 (Hyalgan/Supartz/Visco‑3) series 3–5 weekly injections; J7323 (Euflexxa) 3 weekly injections; J7326 (Gel‑One) single injection; J7327 (Monovisc) single injection.

Per‑dose/unit guidanceEach HCPCS entry includes dose and units (e.g., J7321 dose per knee 20–25 mg once weekly, units = 1; J7328 Gelsyn‑3 dose 16.8 mg once weekly, units = 168 for per 0.1 mg billing).

Other modifier requirementsReport JW/JZ when applicable and follow modifier guidelines; incorrect modifier reporting may cause denials.

Authorization, Documentation, and Payment Considerations

Prior Authorization

Authorization and payment caveat

Authorization and medical necessity rules still apply; prior authorization does not guarantee payment. Providers must obtain any required authorizations and ensure services, coding, and documentation meet medical necessity, coding and billing policy requirements. An authorization on file does not supersede coding, billing or reimbursement requirements, and failure to follow billing/submission or documentation rules may result in claim denial, rejection, or recoupment.

Obtain required authorizations and document medical necessity for the procedure, diagnosis, and frequency.
Ensure claims use industry-standard CPT/HCPCS/revenue codes only when service is performed and fully documented to highest specificity.
Recognize that an authorization is not a guarantee of payment; improper coding, billing, or documentation can lead to denial, rejection, or recovery of payment.
Be prepared for pre- or post-claim payment integrity reviews.

Procedure Definitions

Trigger point injections (TPI)

DefinitionTrigger point injections (TPI) are injections of an anesthetic, saline and possibly a steroid into a muscle to relax muscles causing knots and/or nerve irritation.

Typical purposeGiven to relieve pain by relaxing muscles that are causing knots or irritation to nearby nerves.

Coding noteReport with CPT 20552 when 1–2 muscles are injected and CPT 20553 when 3 or more muscles are injected; reimbursement is one payment per site regardless of number of injections.

Arthrocentesis / Aspiration / Injection

DefinitionArthrocentesis, aspiration, injections use a needle to relieve discomfort, drain infected fluid, or instill medication into a joint or bursa.

Typical purposesRelieve discomfort, remove infected or excess fluid, or deliver medication directly into a joint or bursa.

CodingMajor joint arthrocentesis/aspiration/injection reported with CPT 20610 (without ultrasound) or 20611 (with ultrasound guidance/recording).